Covid-19 Updates & Info

[Deuce]

For her, the opposition to vaccination is a cause, an act of defiance that shows she's smarter than everyone else, and losing her job would fall into the category of righteous martyrdom. That's what my gut says.

That is my take on the majority of people who are against the vaccine.
In my experience, they are insecure people who desperately need to 'prove' something, and so they align themselves with the vocal minority in claiming that they 'know better' than the majority, that they are not followers, etc.
We see the same thing playing out - for the same reasons - in several other elements of life, as well.

I, myself, as anyone who knows me will attest, am quite cynical, and am the opposite of a follower. I also believe that dishonesty, greed, selfishness, and manipulation are inherent elements of politics and politicians at all levels everywhere. But I still got my 2 vaccines as soon as I was able to.

[Deuce]

A valid argument can definitely be made to make every seat on passenger planes ejectable, with the eject button controlled remotely by airline staff...

Eject Button, Please...

.

[ti-amie]

[ti-amie]

[ti-amie]

[dryrunguy]

Here's the latest Situation Report. In particular, the second paragraph under Racial/Ethnic Disparities is pretty stunning.

::

EXTENDED PRIMARY VACCINE SERIES On October 11, the WHO’s Strategic Advisory Group of Experts (SAGE) on Immunization recommended additional doses of SARS-CoV-2 vaccines for immunocompromised individuals. The recommendation applies to all 7 vaccines that have received an Emergency Use Listing (EUL) from the WHO and to all individuals who are moderately or severely immunocompromised individuals. SAGE also recommended a third dose of the Sinopharm and Sinovac vaccines for individuals aged 60 years and older. The advisory group emphasized that countries should initially prioritize administering the full original vaccine regimen to increase vaccination coverage, but an additional dose would provide extra protection for individuals at the highest risk for severe disease.

Notably, SAGE clearly distinguished its updated guidance from booster dose policies being implemented in some countries, including several in Europe, Israel, and the US. Specifically, the additional doses recommended under the new SAGE guidance are intended “as part of an extended primary series since [immunocompromised] individuals are less likely to respond adequately to vaccination” rather than as a general boost to protection for otherwise healthy individuals. The SAGE experts met for 4 days to discuss myriad vaccine-related issues, including non-pandemic topics such as the world’s first malaria vaccine, and the full meeting report is expected to be published in December. Reportedly, SAGE will address waning immunity and the need for broader booster doses in healthy individuals at a meeting scheduled for November 11.

MOLNUPIRAVIR EUA REQUEST Merck and Ridgeback Biotherapeutics on October 11 submitted an application with the US FDA for Emergency Use Authorization (EUA) of molnupiravir, an investigation oral antiviral medication, for the treatment of mild-to-moderate COVID-19 in adults at high risk of severe disease. Notably, if authorized by the FDA, the drug would be the first COVID-19 treatment to be administered orally, as all other authorized or approved medications are delivered intravenously or via injection. The companies’ submission is based on a Phase 3 clinical trial interim analysis showing molnupiravir reduced the risk of hospitalization or death by about half when compared with people who received a placebo. The data are not yet published or peer-reviewed. An effective therapeutic that is taken by people recovering at home could relieve some pressure on hospitals, particularly in areas with low vaccination rates.

Two Indian generic drug manufacturers last week requested permission to end late-stage clinical trials of generic versions of molnupiravir, after the drug did not show “significant efficacy” among people with moderate COVID-19 disease. A Merck spokesperson noted that the Indian studies defined moderate disease differently than the FDA and included patients with more severe disease. The Indian companies are continuing to research the treatment among people with mild COVID-19.

COVID-19 IN PREGNANCY Echoing guidance by the US CDC, England’s National Health Service (NHS England) on October 11 encouraged pregnant people to get vaccinated against SARS-CoV-2 and released data showing that, since July, nearly 1 in 5 of England’s most critically ill COVID-19 patients—those who required intensive care unit support including extracorporeal membrane oxygenation (ECMO)—have been unvaccinated pregnant women. Notably, of all women between the ages of 16 and 49 who have required ECMO in an intensive care unit, 32% of them have been pregnant, up from 6% at the beginning of the pandemic. NHS England is working to dispel misinformation and fears surrounding SARS-CoV-2 vaccines, pointing to safety data showing the shots are safe for pregnant individuals and their fetuses. According to data from the CDC, COVID-19 poses a significantly higher risk to pregnant people compared with non-pregnant people.

Several other recently released studies suggest that pregnant people with symptomatic COVID-19 are at a higher risk of emergency complications and other adverse perinatal and neonatal outcomes. A not-yet-peer-reviewed study presented over the weekend at the Anesthesiology 2021 Annual Meeting and a peer-reviewed study published October 10 in the Journal of Maternal-Fetal & Neonatal Medicine showed that pregnant people with COVID-19 who were symptomatic had an increased risk of giving birth in emergency circumstances and were more likely to have complications endangering their newborns, compared with those who had asymptomatic COVID-19 or who were not infected. Researchers writing in the American Journal of Obstetrics and Gynecology found that the recent surge of the Delta variant was associated with increased morbidity among pregnant people with COVID-19, particularly in underserved populations with low vaccine acceptance, prompting them to highlight the urgency of preventive measures during pregnancy, including vaccination. Additionally, experts attending the recent American Academy of Pediatrics (AAP) virtual meeting discussed neonatal outcomes, an apparent increase in preterm birth incidence among infected pregnant people compared with the 2019 incidence, as well as higher-than-expected maternal mortality among pregnant people testing positive at or around the day of delivery. All of the studies support emerging trends showing that COVID-19 can severely impact pregnant people and neonates, and provide evidence that vaccination is critically important for this population.

MENTAL HEALTH Prior to World Mental Health Day on October 10, a study published online on October 8 in The Lancet documented a grim and startling rise in cases of major depressive disorder (53.2 million new cases; 27.6% increase) and anxiety disorders (76.2 million new cases; 25.6% increase) globally from January 1, 2020 to January 29, 2021. The study was a systematic review of the prevalence of major depressive disorder and anxiety orders during the COVID-19 pandemic across various comprehensive sources, culminating in a meta-regression to estimate the rise in these 2 disorder types during the pandemic associated with COVID-19 impact indicators (e.g. mobility, daily SARS-CoV-2 infection rate). Impact indicators were found to be associated with increased prevalence of major depressive disorder and anxiety disorders, particularly among women and younger age groups.

The US CDC Morbidity and Mortality Weekly Report (MMWR) also published a similar study last week on national and state trends related to anxiety and depression during the pandemic. Findings noted that anxiety severity scores and depression severity scores increased from August 2020 to December 2020 before decreasing until June 2021.

RACIAL/ETHNIC DISPARITIES American Indian/Alaska Native (AI/AN), Black, and Latino individuals in the US have been disproportionately affected by the COVID-19 pandemic, with the disease causing more deaths by population size—both directly and indirectly—among these groups when compared with White or Asian populations. In a study published last week in the Annals of Internal Medicine, researchers reported that during the first 10 months of the pandemic (March-December 2020), an estimated 477,200 excess deaths occurred in the US than would have been expected based on 2019 data. Of these deaths, about 74% were directly attributable to COVID-19. After adjusting for age, overall excess deaths per 100,000 persons in 2020 were 2 to 3 times higher among AI/AN, Black, and Latino individuals compared with White and Asian individuals. Although the reasons for excess mortality are unknown, the researchers noted that “structural and social determinants of health with established and deep roots in racism”—including an increased risk of occupational exposure and lack of access to healthcare, possibly caused by fear during the pandemic—or misattribution of causes of death could have played roles.

The racial and ethnic disparities in COVID-19-related deaths spill over into the pandemic’s impacts on children. According to a modeling study published last week in Pediatrics, children of racial and ethnic minorities accounted for 65% of the more than 140,000 children who experienced orphanhood or lost a caregiver due to COVID-19 between April 2020 and June 2021. Compared to White children, AI/AN children were 4.5 times more likely to lose a caregiver, Black children were 2.4 times more likely, and Hispanic children were 1.8 times more likely. The highest burden of caregiver deaths due to COVID-19 occurred in states on the Southern US border, in the Southeast, and those with tribal areas. The researchers concluded there is an “urgent need” to provide affected children access to support services. An October 8 analysis from the Kaiser Family Foundation using CDC data shows that racial disparities in COVID-19 cases and death rates persist among Black, Hispanic, and AI/AN individuals, but data suggest the gap has recently narrowed for Black and Hispanic people. Notably, AI/AN individuals remain at disproportionate risk for COVID-19 disease and death, despite having the highest vaccination rate across racial/ethic groups. While the narrowing disparity in some groups could be due to increasing vaccination rates, other factors definitely play a role in ongoing disparities, and more research is needed to understand and address them.

AUSTRALIA On October 11, Australia began to emerge from its strict pandemic lockdown when New South Wales (NSW) began to allow fully vaccinated residents to return to restaurants, bars, hair salons, and gyms after nearly 4 months of restrictions. About 74% of NSW residents aged 16 and older are fully vaccinated, enabling the state—including Sydney, Australia’s most populous city—to ease its lockdown despite an ongoing outbreak. NSW State Premier Dominic Perrottet called it a “freedom day” and pledged to lead the nation out of the pandemic, but not without challenges. He warned that the number of new COVID-19 cases will rise following reopening, as virus-free Western Australia and Queensland and other so-called “zero COVID” countries in the Asia-Pacific region watch closely to see whether NSW can adapt to living with COVID-19.

ITALY’S GREEN PASS From October 15 through the end of 2021, Italian workers will be required to present a digital or printed “Green Pass” certificate upon entering their workplace, demonstrating that they have recovered from COVID-19 in the last six months, received a negative COVID-19 rapid antigen test result in the last 48 hours, received a negative COVID-19 molecular test result in the last 72 hours, or have been at least partially vaccinated. Workers who do not comply with the new mandate risk fines or suspension. Both civil and violent protests have broken out in response to the September 16 announcement regarding the new mandate in Italy, including reported clashes over the weekend between neo-fascists or other individuals associated with the far right and police. Some employees and policymakers are concerned that a rise in vaccinations may not occur, instead leading to worker shortages due to a lack of available tests.

The Green Pass already is required in Italy in order to access schools and universities, utilize public transport, participate in gatherings related to civil or religious ceremonies, visit medical facilities or long-term care facilities, access certain public gathering events or spaces, and pass through areas with higher COVID-19 risk—so-called “red” or “orange” zones. The Green Pass also is recognized by the European Union to help travelers avoid COVID-19 travel restrictions.

[ponchi101]

Ok, great for Australia and NSW, but the word FREEDOM will pretty soon lose all recognizable meaning when it is used for anything that remotely relates to real freedom. If the proper explanation is not given, you simply become a parrot saying the word without understanding it.
Somebody has to coin a word that combines FREEDOM and DUTY so it can explain things better.

[dryrunguy]

Here's the latest Situation Report.

::

EPI UPDATE The WHO COVID-19 Dashboard reports 238.5 million cumulative cases and 4.86 million deaths worldwide as of October 13. Global weekly incidence decreased by 6.7% compared to the previous week, and mortality fell by 9.5%.

Global Vaccination
The WHO reported 6.36 billion cumulative doses of SARS-CoV-2 vaccines administered globally as of October 10. A total of 3.63 billion individuals have received at least 1 dose, and 2.64 billion are fully vaccinated. Analysis from Our World in Data indicates that the overall trend in global daily vaccinations continues to decline, down to fewer than 23 million doses per day*. The global trend continues to closely follow Asia. Our World in Data estimates that there are 3.78 billion vaccinated individuals worldwide (1+ dose; 47.97% of the global population) and 2.80 billion who are fully vaccinated (35.56% of the global population).
*The average daily doses administered may exhibit a sharp decrease for the most recent data, particularly over the weekend, which indicates effects of reporting delays. In an effort to reflect the longer-term trends, the numbers reported here may not correspond to the most recent data.

UNITED STATES
The US CDC reports 44.5 million cumulative COVID-19 cases and 716,370 deaths. The US has passed a peak in terms of daily incidence. The most recent high was 161,711 new cases per day on September 1, and the trend began to decline slightly before the Labor Day holiday weekend. The current average is approximately 86,181 new cases per day and appears to be decreasing. Daily mortality also appears to have passed a peak, down from a recent high of 1,815 on September 15 to 1,252 on October 12*.
*Changes in state-level reporting may affect the accuracy of recently reported data, particularly over weekends. In an effort to reflect the longer-term trends, the numbers reported here may not correspond to the most recent dates.

According to an analysis published October 13 by the Peterson Center on Healthcare and the Kaiser Family Foundation, COVID-19 continues to be a leading cause of death in the US. While daily mortality is now falling, COVID-19 was the second leading cause of death in the US in September 2021, behind heart disease, according to the analysis based on US CDC and other data. The majority of COVID-19-related deaths have been among unvaccinated individuals.

US Vaccination
The US has administered 404 million cumulative doses of SARS-CoV-2 vaccines. The daily vaccination trend rose briefly following authorization of booster doses of the Pfizer-BioNTech vaccine for some populations on September 22 but is now declining after a recent peak on October 1*. There are 217.6 million individuals who have received at least 1 dose, equivalent to 65.6% of the entire US population. Among adults, 78.5% have received at least 1 dose, as well as 14.7 million adolescents aged 12-17 years. A total of 187.9 million individuals are fully vaccinated, which corresponds to 56.6% of the total population. Approximately 68% of adults are fully vaccinated, as well as 12.1 million adolescents aged 12-17 years.
*Due to delays in reporting, estimates for the average daily doses administered are less accurate for the most recent 5 days. The most current average provided here corresponds to 5 days ago.

VACCINE BOOSTERS The US FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) is meeting today to discuss Moderna’s request for authorization of an additional dose of its SARS-CoV-2 vaccine and on October 15 to discuss a similar request from J&J-Janssen. Any recommendations the committee makes are used to help the FDA make decisions but are not binding. Moderna has asked regulators to authorize an additional half-dose of its vaccine for adults aged 65 and older—a decision which appears to already be made based on questions submitted to the committee—and individuals at high risk of severe COVID-19, similar to the authorization granted last month for the Pfizer-BioNTech vaccine. An FDA briefing document released this week suggests that a booster dose of Moderna’s vaccine administered at least 6 months from the second dose increased antibody levels in recipients. However, the difference of the levels before and after the booster dose was not wide, and the agency did not take a position on whether the extra dose was necessary. The panel also will discuss the risk of post-vaccination myocarditis and other adverse reactions and whether data show efficacy of the Moderna vaccine is waning. In separate documents submitted to the FDA, Moderna said a half-dose (50μg) additional shot provided similar increases in antibody levels as the full dose (100μg) but with fewer side effects.

During the second day of meetings, VRBPAC will consider whether data presented by J&J-Janssen supports a booster dose for its single-dose SARS-CoV-2 vaccine, and when the additional dose should be administered. In a briefing document released October 13, the FDA said there “may be a benefit” in giving a second dose about 2 months after the primary dose and made it clear that while the J&J-Janssen vaccine provides protection against severe COVID-19, it is less effective than the mRNA vaccines from Moderna and Pfizer-BioNTech. However, the agency questioned the sample sizes of the studies showing a benefit and did not provide a clear conclusion on whether the panel would recommend booster doses for certain populations.

VRBPAC also likely will discuss “mixing and matching” vaccines but is not expected to make recommendations on the approach. Highly anticipated results from a US NIH-sponsored study were posted to the preprint server medRxiv on October 13, suggesting that recipients of the J&J-Janssen vaccine might produce a more intense immune response to a booster dose of an mRNA vaccine than an additional dose of the J&J-Janssen vaccine. Individuals who initially received either the Moderna or Pfizer-BioNTech vaccines and received a third dose of either shot showed similarly strong immune responses, according to the study, which is not yet peer-reviewed. The US CDC’s Advisory Committee on Immunization Practices (ACIP) is scheduled to meet next week to discuss the FDA’s recommendations on booster doses. If regulators eventually decide to permit mixing and matching vaccines, the FDA will have to amend the authorizations of both mRNA vaccines to permit them to be used to boost the J&J-Janssen vaccine.

US TRAVEL REQUIREMENTS The US plans to ease travel restrictions in November for fully vaccinated individuals crossing its land borders with Canada and Mexico, marking a reopening to travelers and tourists after being closed for more than 18 months. Unvaccinated individuals will continue to be banned from crossing the country’s northern and southern borders for nonessential travel. The new rules—which coincide with and are similar to recently updated guidance for air travelers—will be implemented in phases, with vaccinated visitors traveling for nonessential reasons to be allowed to cross land borders in November, and all inbound travelers, whether essential or nonessential, needing proof of vaccination by January 2022. Canada reopened its US border to nonessential travel by fully vaccinated US residents in August, and Mexico never closed its northern border. Several US Members of Congress representing border states welcomed the rule changes, as closures had separated cross-border families and wrought financial tolls on border cities. Notably, the US will keep in place a separate immigration policy that allows the government to deport or turn away any migrants who are seeking asylum or economic opportunity.

VACCINE MANDATES Since US President Joe Biden announced SARS-CoV-2 vaccination requirements for federal workers and contractors, healthcare systems, and employers with 100 or more employees, most workers have chosen to be vaccinated, despite some predictions mandates might worsen labor shortages by prompting widespread resignations. The requirements boosted vaccination rates by at least 20 percentage points, White House officials said on October 13. Aerospace company Boeing and Southwest Airlines are the latest large corporations to announce their employees must be vaccinated or receive exemptions by December 8, in compliance with new federal guidelines expected to be finalized soon. However, confusion arose for Texas-based Southwest and American Airlines, as well as other companies, on October 11, as Texas Governor Greg Abbott signed an executive order extending bans on COVID-19 vaccine mandates by any entity in the state, including private employers, and broadening reasons for exemptions. A previous executive order from Governor Abbott bans vaccine requirements by government agencies, cities, counties, and school districts in the state. Both Southwest and American indicated they will maintain their vaccine requirements for employees. Most other companies also likely will follow the federal rule, as federal law takes precedence over state law under the Supremacy Clause of the US Constitution. But questions over the conflicting laws remain.

In Florida, the state Department of Health levied a fine of more than US$3.5 million on Leon County for requiring county employees to be vaccinated, in violation of a state law. Under the law, government agencies can be fined US$5,000 for each violation of requiring vaccination as a condition of employment. The state said Leon County violated the law 714 times, for each of its employees, accruing a fine of US$3.57 million it must pay within 30 days. The Leon County administrator called the ban politically motivated and vowed to enforce the county vaccine mandate “using any remedies available.”

In New York, a federal judge on October 12 issued a preliminary injunction barring state health officials from interfering with employers who allow religious exemptions to state-imposed vaccination mandates for all healthcare workers. Judge David N. Hurd of the Northern District said the state overreached by barring all religious accommodations in its mandate and wrote that the 17 healthcare workers who filed the lawsuit were likely to succeed. New York Governor Kathy M. Hochul vowed to appeal the ruling. The case (Dr. A et al v. Hochul) provides a test for strict vaccine mandates covering healthcare workers. At least 23 states require SARS-CoV-2 vaccination for healthcare workers.

SARS-COV-2 ORIGIN The WHO on October 13 announced 26 proposed members of its new Scientific Advisory Group for the Origins of Novel Pathogens (SAGO), which is tasked with creating a global framework to define and guide investigations into the origins of emerging and re-emerging diseases of epidemic and pandemic potential, including SARS-CoV-2. The scientists, hailing from 26 different nations, have expertise in a wide range of areas, from molecular biology to animal health and include 6 members of the previous 10-person joint WHO-China mission that investigated the COVID-19 pandemic’s origins and issued inconclusive findings more than 6 months ago. The WHO said the renewed effort might be the “last chance” to find the virus’s origins, but some questioned whether an advisory board will have the power to make inroads with China, which has not been a very cooperative partner. This week, Chinese officials said the country plans to test up to 200,000 blood bank samples from the city of Wuhan, where the virus was first identified in December 2019. The samples have been in storage for 2 years and could help provide clues as to when and where the virus first appeared in humans.

In an editorial published the same day in Science, WHO leadership encouraged that all origin possibilities be investigated, including the so-called “lab-leak theory” that the virus inadvertently escaped a laboratory in Wuhan. Notably, the previous WHO investigation deemed that theory “very unlikely.” Chinese officials continue to encourage researchers to look in other countries for clues but have said they will work within the framework of SAGO. The WHO plans to finalize the SAGO members following a 2-week public consultation period. Although the window of opportunity for finding the origins of the current pandemic is closing, and many questions remain unanswered, learning more about the origins of SARS-CoV-2 could help prevent the next outbreak.

FLU SEASON Medical professionals and public health experts worldwide are urging everyone to receive their flu vaccine in advance of what could be a particularly severe flu season this coming winter. Last year, SARS-CoV-2 appeared to displace most of the circulating seasonal influenza viruses with 1 pediatric flu death in the US for 2020 compared to 75-150 pediatric deaths in previous seasons. This year, experts are warning of a “twindemic” of COVID-19 and flu cases, as pandemic restrictions are easing. Since there were relatively few cases of flu last year, experts worry that immunity against the flu will be lower in the general population this year, potentially resulting in more cases and hospitalizations. Unlike with SARS-CoV-2 vaccines, flu vaccines are approved for children 6 months and older. Combined with effective respiratory disease control measures, such as masking and physical distancing, it is doubly important this year to obtain a flu vaccine. A recent study published in PLoS One suggested that flu shots could have protective effects against COVID-19 severe outcomes. In a retrospective cohort of more than 74,000 patients hospitalized with COVID-19, those who had received a flu vaccine had significantly lower risks of sepsis, stroke, and subsequent emergency department visits for COVID-19-related outcomes. More studies are needed to further examine this possible correlation, but the results are encouraging to solidify the case for all eligible persons to get their flu vaccine.

CUREVAC CureVac announced October 12 that it is withdrawing its first-generation SARS-CoV-2 mRNA vaccine candidate, CVnCoV, from the current approval process with the European Medicines Agency (EMA) to instead focus on developing second-generation mRNA vaccine candidates in collaboration with GlaxoSmithKline (GSK). The company also terminated an advance agreement with the European Commission (EC) for the sale of 405 million doses of the vaccine after approval. The announcement represents the seventh vaccine candidate to be abandoned after clinical trials, in part due to the success of mRNA vaccines from Pfizer-BioNTech and Moderna.

ABUSE OF SCIENTISTS A self-selecting survey by Nature of more than 300 scientists who have spoken publicly about COVID-19 in media interviews or on social media found 15% said they had received death threats, with nearly 60% of those surveyed saying they had faced other forms of harassment or abuse. Notably, most researchers said their experiences with media interviews were positive but those who reported the highest frequency of personal attacks or trolling were also the most likely to indicate a reduced willingness to speak with the media in the future. Nature predicts that these results could have a “chilling effect” on science communication.

https://covid19.who.int/

[ti-amie]

[JazzNU]

Penn State has done a whole lot of nothing in the way of vaccine mandates for faculty, staff, and students up until now, they have only strongly encouraged getting the vaccine, but they will institute a mandate for faculty and staff by December. And it's to be in compliance with Biden's federal mandate. So I thought I'd mention it to give you guys a better idea of the reach of that mandate.

All PSU faculty and staff must be fully vaccinated by December 8th. "Staff" includes full and part time workers, technical service, and any students or graduate students that get paid by the university in any fashion. The mandate applies whether you work on main campus or remotely.

PSU estimated that between labs and other research projects that they have 1,000 federal contracts at the main campus. One thousand. That's just one school (though granted, a very large one). Given this extends to university research, it be will be very difficult for public or private research universities of any size to avoid this mandate. Some are taking the approach that this doesn't apply in that manner, and that's a bold (and dumb) strategy to take with the federal research gravy train universities ride on. We'll see how it plays out. University of Delaware and PSU appear to be two of the first public universities to take this step, private universities have had similar announcements before this. I'm thinking we'll be seeing more announcements because they can't risk it.

[dryrunguy]

Our tobacco retailer inspection teams will also be required to be vaccinated. That includes inspectors, underage purchasers (ages 16-20 depending on the state or jurisdiction), and chaperones. These are folks that might bill, on average, only 10-15 hours a month to our inspection contracts.

That might not seem like a big deal, but if you take into account the states and jurisdictions where we conduct/will be conducting inspections--Nevada, Idaho, Pennsylvania, Puerto Rico, New Mexico, Oregon, Alaska, Utah, and Wyoming--well, let's just say most of those are not exactly vaccination-enthusiastic parts of the United States.

To further complicate things, our parent company is providing a one-time incentive payment of $500 for all staff who provide proof of vaccination to HR, but that incentive does not extend to on call personnel, which includes any employees who bill less that 50% per month, such as our inspectors, underage purchasers, and chaperones. I'm trying to get that changed, but I'm not feeling particularly optimistic.

[ponchi101]

$500 incentive. I paid two tickets to the USA to get vaccinated.
IATA.

[dryrunguy]

$500 incentive. I paid two tickets to the USA to get vaccinated.
IATA.

Yup. The dissonance has been mentioned here before. You have people all over the world begging for a vaccine and not even caring if it's a GOOD vaccine.

Meanwhile, in the U.S., you have companies offering employees incentives to get vaccinated, which is free, and instead you have covidiots paying $300 or more for a fake vaccination card.

It makes no sense.

[MJ2004]

Halloween 2021

[ti-amie]

Halloween 2021